NASDAQ:ILMN Illumina (ILMN) Stock Price, News & Analysis $136.02 +2.02 (+1.51%) (As of 12/20/2024 05:51 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Illumina Stock (NASDAQ:ILMN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Illumina alerts:Sign Up Key Stats Today's Range$133.08▼$137.6950-Day Range$130.74▼$155.1552-Week Range$100.08▼$156.66Volume14.35 million shsAverage Volume2.06 million shsMarket Capitalization$21.57 billionP/E RatioN/ADividend YieldN/APrice Target$165.95Consensus RatingModerate Buy Company OverviewIllumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.Read More… Illumina Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks90th Percentile Overall ScoreILMN MarketRank™: Illumina scored higher than 90% of companies evaluated by MarketBeat, and ranked 110th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingIllumina has received a consensus rating of Moderate Buy. The company's average rating score is 2.70, and is based on 10 buy ratings, 8 hold ratings, and no sell ratings.Amount of Analyst CoverageIllumina has been the subject of 14 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Illumina's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth7.54% Earnings GrowthEarnings for Illumina are expected to grow by 7.54% in the coming year, from $4.11 to $4.42 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Illumina is -13.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Illumina is -13.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIllumina has a P/B Ratio of 3.76. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.55% of the outstanding shares of Illumina have been sold short.Short Interest Ratio / Days to CoverIllumina has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Illumina has recently increased by 10.24%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldIllumina does not currently pay a dividend.Dividend GrowthIllumina does not have a long track record of dividend growth. Sustainability and ESG4.2 / 5Environmental Score-1.11 Percentage of Shares Shorted4.55% of the outstanding shares of Illumina have been sold short.Short Interest Ratio / Days to CoverIllumina has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Illumina has recently increased by 10.24%, indicating that investor sentiment is decreasing significantly. News and Social Media3.8 / 5News Sentiment0.82 News SentimentIllumina has a news sentiment score of 0.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for Illumina this week, compared to 14 articles on an average week.Search Interest43 people have searched for ILMN on MarketBeat in the last 30 days. This is an increase of 87% compared to the previous 30 days.MarketBeat Follows7 people have added Illumina to their MarketBeat watchlist in the last 30 days. This is an increase of 75% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Illumina insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.17% of the stock of Illumina is held by insiders.Percentage Held by Institutions89.42% of the stock of Illumina is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Illumina's insider trading history. Receive ILMN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Illumina and its competitors with MarketBeat's FREE daily newsletter. Email Address ILMN Stock News HeadlinesGRAIL: Biotech Stock Targeting $100B Cancer Market (ILMN)GRAIL is a small biotech stock on the rise big time recently. Its innovative technology gives it the opportunity to capitalize on a massive addressable market.December 14, 2024 | marketbeat.comIllumina And Grail In 2025? Grounds For Optimism, If Mistakes Aren't RepeatedDecember 19 at 4:46 PM | seekingalpha.comURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.December 22, 2024 | Crypto Swap Profits (Ad)Illumina, Inc. (ILMN) Sees Modest Gains Amid Regulatory Approvals and Market SpeculationDecember 19 at 4:46 PM | insidermonkey.comIllumina (ILMN) was downgraded to a Hold Rating at CitiDecember 17, 2024 | markets.businessinsider.comOvation.io and Illumina Collaborate to Advance Genomic Data ResearchDecember 17, 2024 | businesswire.comWhat's Going On With Illumina Stock On Monday?December 16, 2024 | benzinga.comMicroStrategy’s Stock Added To The Nasdaq 100 IndexDecember 16, 2024 | baystreet.caSee More Headlines ILMN Stock Analysis - Frequently Asked Questions How have ILMN shares performed this year? Illumina's stock was trading at $139.24 at the beginning of 2024. Since then, ILMN stock has decreased by 2.3% and is now trading at $136.02. View the best growth stocks for 2024 here. How were Illumina's earnings last quarter? Illumina, Inc. (NASDAQ:ILMN) released its quarterly earnings data on Monday, November, 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.88 by $0.26. Illumina's revenue for the quarter was down 3.5% on a year-over-year basis. Read the conference call transcript. Does Illumina have any subsidiaries? Illumina subsidiaries include Grail, Enancio, BlueBee, Edico Genome, Conexio Genomics, GenoLogics, NextBio, and more. Who are Illumina's major shareholders? Top institutional investors of Illumina include State Street Corp (3.54%), Loomis Sayles & Co. L P (2.74%), Baillie Gifford & Co. (2.27%) and WCM Investment Management LLC (2.05%). Insiders that own company stock include Susan H Tousi, Jacob Thaysen, Aimee L Hoyt, Charles Dadswell, Phillip G Febbo and Alexander Aravanis. View institutional ownership trends. How do I buy shares of Illumina? Shares of ILMN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Illumina own? Based on aggregate information from My MarketBeat watchlists, some other companies that Illumina investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), Netflix (NFLX), Visa (V) and Alphabet (GOOG). Company Calendar Last Earnings11/04/2024Today12/22/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Analytical instruments Sub-IndustryLife Sciences Tools & Services Current SymbolNASDAQ:ILMN CUSIP45232710 CIK1110803 Webwww.illumina.com Phone(858) 202-4500Fax858-202-4766Employees9,300Year Founded1998Price Target and Rating Average Stock Price Target$165.95 High Stock Price Target$254.00 Low Stock Price Target$115.00 Potential Upside/Downside+22.0%Consensus RatingModerate Buy Rating Score (0-4)2.70 Research Coverage20 Analysts Profitability EPS (Most Recent Fiscal Year)($9.96) Trailing P/E RatioN/A Forward P/E Ratio33.09 P/E GrowthN/ANet Income$-1,161,000,000.00 Net Margins-36.10% Pretax Margin-34.92% Return on Equity7.29% Return on Assets3.40% Debt Debt-to-Equity Ratio0.94 Current Ratio2.43 Quick Ratio1.85 Sales & Book Value Annual Sales$4.39 billion Price / Sales4.91 Cash Flow$3.30 per share Price / Cash Flow41.20 Book Value$36.18 per share Price / Book3.76Miscellaneous Outstanding Shares158,600,000Free Float158,330,000Market Cap$21.57 billion OptionableOptionable Beta1.11 Social Links The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report This page (NASDAQ:ILMN) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | SponsoredThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored2025’s #1 Trump TradeAll the Energy You Need to Power Your Entire Life... Could Fit Inside This Single Soda Can. Three Companies...The Oxford Club | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Illumina, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Illumina With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.